Elaia

Elaia is a Paris-based venture capital firm established in 2002, managing over €700m. It specializes in early-stage investments, focusing on disruptive startups in the digital economy, deep tech, and software technology sectors across Europe and Israel. With a team boasting over 75 years of combined experience in venture capital and digital industries, Elaia provides close, proactive support to its entrepreneurs, aiming to help them grow into global leaders.

Sofia Dahoune

Investor

Florian Denis

Investment Director

Clément Vanden Driessche

Investment Director

Clement Vanden Driessche

Investment Director

Gabriel Franz

Investment Manager

Alexis Frentz

Investment Director

Benoit Georis

Investment Director

Amélie Juge

Associate

Samantha Jerusalmy

Partner

Franck Lescure

Partner

Maxime Lhoustau

Associate

Sacha Loiseau

Venture Partner

Gabriel Levy

Associate

Julien Macquet

Associate

Alexandre Ouimet-Storrs

Venture Partner

Céline Passedouet

Investment Director

Emmanuel Perez-Duarte

CFO

Daniel Pilaud

Venture Partner

Christophe Primault

Venture Partner

Marc Rougier

Partner

Manon Sorroche

Associate

David Sourdive

Venture Partner

Armelle de Tinguy

Investment Manager

Past deals in Hospital

Hema.to

Seed Round in 2025
Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.

Hema.to

Seed Round in 2023
Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.

LynxCare

Series A in 2022
LynxCare, established in 2015 and headquartered in San Francisco, specializes in an AI-driven data platform. It collects and analyzes structured and unstructured data from diverse sources, offering hospitals and clinics actionable insights to enhance clinical efficiency and improve patient care quality.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.